Zobrazeno 1 - 1
of 1
pro vyhledávání: '"relapse or refractory lymphoma"'
Autor:
Josée M. Zijlstra, Anita Joshi, Marie Maerevoet, Joost S.P. Vermaat, Eric Van Den Neste, Kelly Corona, Fatima De la Cruz, Olivier Casasnovas, Andre Goy, Michael W. Schuster, Reda Bouabdallah, Sourav Mishra, Sharon Shacham, Sameer Bakhshi, George A Follows, Michael Kauffman, Hongwei Wang, Yosef Landesman, Juan-Manuel Sancho, Theodoros P. Vassilakopoulos, Miguel Canales, Federica Cavallo, Jean Richard Saint-Martin, Catherine Thieblemont, Hua Chang, Nada Hamad, Miklos Egyed, Nagesh Kalakonda, Ulrich Jaeger, Ronit Gurion, Fritz Offner, Krzysztof Warzocha, Daniel McCarthy, Xiwen Ma, Sylvain Choquet, Brian T. Hill, Jatin P. Shah
Publikováno v:
The Lancet Haematology, 7(7), e511-e522. Lancet Publishing Group
Kalakonda, N, Maerevoet, M, Cavallo, F, Follows, G, Goy, A, Vermaat, J S P, Casasnovas, O, Hamad, N, Zijlstra, J M, Bakhshi, S, Bouabdallah, R, Choquet, S, Gurion, R, Hill, B, Jaeger, U, Sancho, J M, Schuster, M, Thieblemont, C, De la Cruz, F, Egyed, M, Mishra, S, Offner, F, Vassilakopoulos, T P, Warzocha, K, McCarthy, D, Ma, X, Corona, K, Saint-Martin, J R, Chang, H, Landesman, Y, Joshi, A, Wang, H, Shah, J, Shacham, S, Kauffman, M, Van Den Neste, E & Canales, M A 2020, ' Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial ', The Lancet Haematology, vol. 7, no. 7, pp. e511-e522 . https://doi.org/10.1016/S2352-3026(20)30120-4
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Kalakonda, N, Maerevoet, M, Cavallo, F, Follows, G, Goy, A, Vermaat, J S P, Casasnovas, O, Hamad, N, Zijlstra, J M, Bakhshi, S, Bouabdallah, R, Choquet, S, Gurion, R, Hill, B, Jaeger, U, Sancho, J M, Schuster, M, Thieblemont, C, De la Cruz, F, Egyed, M, Mishra, S, Offner, F, Vassilakopoulos, T P, Warzocha, K, McCarthy, D, Ma, X, Corona, K, Saint-Martin, J R, Chang, H, Landesman, Y, Joshi, A, Wang, H, Shah, J, Shacham, S, Kauffman, M, Van Den Neste, E & Canales, M A 2020, ' Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial ', The Lancet Haematology, vol. 7, no. 7, pp. e511-e522 . https://doi.org/10.1016/S2352-3026(20)30120-4
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single-agent selinexor, an oral selective inhibitor of nuclear e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7a5caa4328ab8a348c48fb45df0a5c5
https://doi.org/10.1016/s2352-3026(20)30120-4
https://doi.org/10.1016/s2352-3026(20)30120-4
